In the adult mammalian CNS, chondroitin sulfate proteoglycans (CSPGs) and myelin-associated inhibitors (MAIs) stabilize neuronal structure and restrict compensatory sprouting following injury. The Nogo receptor family members NgR1 and NgR2 bind to MAIs and have been implicated in neuronal inhibition. We found that NgR1 and NgR3 bind with high affinity to the glycosaminoglycan moiety of proteoglycans and participate in CSPG inhibition in cultured neurons. Nogo receptor triple mutants (Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− ; which are also known as Rtn4r, Rtn4rl2 and Rtn4rl1, respectively), but not single mutants, showed enhanced axonal regeneration following retro-orbital optic nerve crush injury. The combined loss of Ngr1 and Ngr3 (Ngr1 −/− ; Ngr3 −/− ), but not Ngr1 and Ngr2 (Ngr1 −/− ; Ngr2 −/− ), was sufficient to mimic the triple mutant regeneration phenotype. Regeneration in Ngr1 −/− ; Ngr3 −/− mice was further enhanced by simultaneous ablation of Rptps (also known as Ptprs), a known CSPG receptor. Collectively, our results identify NgR1 and NgR3 as CSPG receptors, suggest that there is functional redundancy among CSPG receptors, and provide evidence for shared mechanisms of MAI and CSPG inhibition. npg
a r t I C l e S In the adult mammalian CNS, structural neuronal plasticity is restricted by a number of extrinsic (environmental) and cell-intrinsic growth inhibitory mechanisms 1, 2 . Although such mechanisms are believed to be important for stabilization of intricate networks of neuronal connectivity in CNS health, they also limit adaptive neuronal growth and sprouting following brain or spinal cord injury. Spontaneous repair following severe CNS injury is incomplete and is commonly associated with permanent neurological deficits. Thus, a detailed understanding of the mechanisms that block neuronal growth and repair is of great interest, both biologically and clinically.
A large number of CNS inhibitory cues have been identified [2] [3] [4] . In experimental animal models of spinal cord injury, acute blockage of MAIs 5, 6 or enzymatic degradation of CSPGs with chondroitinase ABC (Ch'aseABC) [7] [8] [9] promotes neuronal sprouting and correlates with improved behavioral outcomes.
The best characterized MAIs are the reticulon family member Nogo, myelin-associated glycoprotein (MAG) and oligodendrocyte myelin glycoprotein (OMgp) 2 . Three isoforms of Nogo have been identified, all of which contain a 66 amino-acid loop (Nogo66) that signals neuronal inhibition. Mechanistic studies have identified the Nogo66 receptor-1 (NgR1) and paired immunoglobulin (Ig)-like receptor B (PirB) as functional receptors for MAIs 10, 11 . NgR1 is comprised of 8.5 leucine-rich repeats (LRRs), flanked by N-terminal (NT) and C-terminal (CT) LRR capping domains. The NT-LRR-CT cluster of NgR1 is fused to a ~100 amino-acid residue stalk region and connected to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor 11 . NgR1 and its close relative NgR2 show overlapping, yet distinct, binding preferences toward MAIs. Nogo66 and OMgp bind selectively to NgR1 (ref. 2) , whereas MAG associates with NgR1 and NgR2 (ref. 12) . The related molecule NgR3 is poorly characterized, and no functional NgR3 ligand(s) have been identified to date. In vitro, loss of Ngr1 renders neurons more resistant to Nogo66-, MAG-and OMgp-induced growth cone collapse, but not to longitudinal neurite outgrowth inhibition on substrate-bound inhibitors [13] [14] [15] . MAIs activate RhoA, RockII and conventional isoforms of protein kinase C (PKC) to destabilize the neuronal cytoskeleton 16, 17 . Similar to NgR1, PirB supports binding of Nogo66, MAG and OMgp. In culture, functional ablation of Pirb (also known as Lilrb3) promotes neurite outgrowth on substrate-bound MAIs and crude CNS myelin. Notably, the combined perturbation of PirB and NgR1 signaling leads to a further release of neurite outgrowth inhibition on crude CNS myelin, but not on recombinant Nogo66 or MAG 10 .
CSPGs are a diverse class of extracellular matrix molecules that influence axonal growth and guidance of developing neurons 18 . a r t I C l e S Following injury to the adult CNS, CSPG expression is upregulated and CSPG is abundant in reactive astrocytes associated with glial scar tissue 4, 19, 20 . CSPGs are comprised of a protein core with covalently attached glycosaminoglycan (GAG) side chains. GAG chains are large, unbranched polymers composed of ~20-200 repeating disaccharide units. Chondroitin sulfate (CS)-GAGs contain alternating units of N-acetyl-galactosamine and glucuronic acid. Most commonly, the hydroxyl groups at position 4 (CS-A) or position 6 (CS-C) of N-acetylgalactosamine are sulfated. In CS-B, iduronic acid replaces glucuronic acid in the chondroitin sulfate disaccharide unit. In CS-D and CS-E, two sulfate groups per disaccharide unit are present. CSPG inhibition is largely abrogated by bacterial Ch'aseABC, indicating that CS-GAGs are important for neuronal growth inhibition 7, 8, 21, 22 .
Similar to MAIs, CSPG-mediated inhibition depends on activation of RhoA and conventional PKCs 16, 17, 23 . Mechanistic studies recently identified the receptor protein tyrosine phosphatase sigma (RPTPσ) as a high-affinity receptor for CSPGs 24 . RPTPσ is a member of the leukocyte common antigen-related protein (LAR) family that also includes LAR and RPTPδ. RPTPσ binds to CS-GAG chains and the structurally related heparan sulfate (HS)-GAG chains via its first Ig-like domain 24, 25 . The association of RPTPσ with CS-and HS-GAGs critically depends on the presence of an evolutionarily conserved cluster of basic amino acid residues. Functional ablation of Rptpσ enhances neurite outgrowth in the presence of CSPGs in vitro and, following CNS injury, promotes growth of sensory afferents 24 , corticospinal tract axons 26 and retinal ganglion cell axons 27 . The incomplete release of CSPG inhibition in Rptpσ-deficient neurons suggests the existence of additional mechanisms of CSPG inhibition. We identified the Nogo receptor (NgR) family members NgR1 and NgR3 as CSPG receptors.
RESULTS

NgRs participate in prototypic MAI-independent inhibition
To determine the role of Nogo receptor family members in CNS myelin inhibition, we generated Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice ( Supplementary Fig. 1 ). Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice are born at Mendelian ratios, viable into adulthood, fertile and indistinguishable from wild-type littermate controls at the gross anatomical level. When plated on crude CNS myelin, postnatal day 7 (P7) cerebellar granule neurons (CGNs), but not dorsal root ganglion (DRG) neurons, of Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice showed a significant (P < 0.001, one way ANOVA, Tukey's post hoc), yet incomplete, release of growth inhibition ( Fig. 1 and Supplementary Fig. 2 ). Compared with CGNs isolated from wild-type, Ngr1 −/− , Ngr1 −/− ; Ngr2 −/− or Ngr3 −/− mice, CGNs from Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mutants grew significantly longer neurites on myelin (P < 0.001, one-way ANOVA, Tukey's post hoc). Notably, in two different types of neurons, CGNs and DRGs, the combined loss of Ngr1 and Ngr2 did not result in enhanced neurite growth on crude CNS myelin ( Fig. 1 and Supplementary Fig. 2 ). Because only NgR1 and NgR3, but not NgR2, are expressed in P7 CGNs 12, 15 , this suggests that NgR3 participates in myelin inhibition. This is somewhat surprising, as NgR3 does not associate with recombinant Nogo, MAG or OMgp 12 .
To directly test whether NgR3 participates in the neurite outgrowth inhibition induced by endogenously expressed Nogo, MAG, or OMgp, we repeated our experiments with CNS myelin isolated from Nogo (also known as Rtn4), Mag and Omgp (also known as Omg) triple mutant mice (Nogo −/− ; Mag −/− ; Omgp −/− ) 28 . Consistent with previous reports 28, 29 , Nogo −/− ; Mag −/− ; Omgp −/− myelin was less inhibitory than wild-type myelin ( Fig. 1 and Supplementary Fig. 2) . Notably, on Nogo −/− ; Mag −/− ; Omgp −/− myelin, CGNs from Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice continued to extend longer neurites (P < 0.001, one way ANOVA, Tukey's post hoc) than CGNs from wild-type, Ngr1 −/− , Ngr1 −/− ; Ngr2 −/− , or Ngr3 −/− mice ( Fig. 1) . This observation indicates that NgR3 participates in Nogo-, MAG-and OMgp-independent growth inhibition. Because the loss of Ngr1 or Ngr3 alone were not sufficient to promote growth on myelin, this suggests that there is some degree of functional redundancy among these two receptors.
NgR1 and NgR3, but not NgR2, associate with neural GAGs To identify candidate NgR3 ligand(s), we generated alkaline phosphatase (AP)-tagged receptor fusion proteins and assayed binding to rat brain tissue sections. Prior to the onset of CNS myelination, NgR1 and NgR3, but not NgR2, bound strongly to numerous fiber tracts in the brain and spinal cord ( Fig. 2a) . After myelination, a more uniform binding pattern was observed, with a much less pronounced labeling of fiber tracts (data not shown). Notably, brain sections of Nogo −/− ; Mag −/− ; Omgp −/− and Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− triple mutants, p75 −/− (also known as Ngfr) single mutants, and mice a WT BSA WT myelin npg a r t I C l e S lacking select gangliosides showed no substantial reduction in soluble receptor binding ( Supplementary Fig. 3 ). In COS-7 cells, components of the NgR1 holoreceptor complex, including p75, TROY and Lingo-1 (ref. 30 ), failed to support NgR3 binding ( Supplementary Fig. 4 ). This suggests that binding of NgR3 to brain is not mediated by previously identified components of the NgR1 complex. Receptor deletion studies further revealed that the LRRs were not required for binding, and identified two discontinuous and evolutionarily conserved sequence motifs in both NgR1 and NgR3 that were necessary for binding to brain ( Fig. 2b-e and data not shown). Motif 1 is located in the C-terminal capping domain and overlaps with the FRG motif, which was previously shown to participate in sialic acid-dependent binding of the ganglioside GT1b to NgR1 (ref. 31 ). Motif 2, separated from motif 1 by approximately 130 amino acid residues, was located near the juxtamembrane region of the NgR1 and NgR3 stalk domain. In NgR1 and NgR3, motif 2 was comprised of a highly conserved cluster of basic amino acid residues, deletion of which completely abolished binding to brain ( Fig. 2b-e ). Furthermore, a soluble form of NgR1 in which the basic residues of motif 2 were replaced by seven alanines (NgR1(7ala)-Fc) no longer bound to brain tissue ( Fig. 2d) .
Ngr3
To assess whether the association of NgR1 and NgR3 with neural tissue is the result of a protein-protein interaction, we subjected brain sections to heat or protease treatment. Binding was largely resistant to either treatment ( Supplementary Fig. 3 ), suggesting a possible interaction with neural glycan(s). Pretreatment of brain tissue sections with various glycosidases revealed a sensitivity to heparinase and Ch'aseABC. Moreover, in the presence of heparin, binding was completely abolished ( Fig. 3a and Supplementary Fig. 3 ). Together, these findings suggest that NgR1 and NgR3 associate with neural GAGs.
NgR1 and NgR3 complex with select CS-GAGs
To examine the specificity of the GAG association, we pre-incubated AP-NgR1 and AP-NgR3 fusion proteins with various types of CS-GAGs. CS-B, CS-D and CS-E, but not CS-A or CS-C, effectively competed with soluble NgR1 and NgR3 for binding to brain sections ( Fig. 3b) . To test whether NgR1 and NgR3 bind to purified GAGs directly, we developed a sandwich ELISA, in which biotinylated GAGs were adsorbed to streptavidin-coated microtiter plates and then incubated with soluble alkaline phosphatase-tagged NgRs ( Supplementary  Fig. 5a ). Consistent with binding experiments to rat brain tissue, NgR1 and NgR3 bound robustly to heparin and purified CS-GAGs, indicating that these receptors bind GAGs directly ( Fig. 3c and Supplementary  Fig. 5b ). NgR1 and NgR3 bound with high specificity and selectivity to different types of monosulfated and disulfated GAGs. Strong binding was observed to monosulfated CS-B and disulfated CS-D and CS-E. The dissociation constants for these interactions were in the low nanomolar range ( Fig. 3c and Supplementary Fig. 5b ). No interactions with CS-A or CS-C were detected. This argues against a nonspecific interaction with negatively charged compounds and underscores the selectivity of the NgR1-and NgR3-GAG associations.
Notably, the first three Ig-like domains of RPTPσ (RPTPσ(1-3)) showed very similar GAG-binding profiles ( Fig. 3c) . At increasing doses, RPTPσ(1-3)-Fc effectively competed with NgR1 for binding to CS-E, indicating that these two receptors complex with, at least in part, overlapping CS-GAG epitopes (Supplementary Fig. 5c ). Functional studies with primary neurons revealed that soluble RPTPσ(1-3)-Fc and NgR1-Fc blocked the growth inhibitory activity of CSPGs toward P7 CGNs in vitro. The neutralizing effects of NgR1-Fc critically depended on the presence of the GAG-binding motif 2, as soluble NgR1(7ala)-Fc failed to block CSPG inhibition ( Fig. 3d) . Figure 2 NgR1 and NgR3, but not NgR2, contain two discontinuous and evolutionarily conserved sequence motifs that are necessary for binding to brain tissue. (a) Coronal sections of embryonic day 18 (E18) rat brain showing the binding pattern of AP-NgR1 and AP-NgR3. No binding was observed for AP-NgR2. Scale bar represents 250 µm. (b,c) Binding of NgR1-Fc (b) and NgR3-Fc (c) to E18 brain sections was abolished following deletion of a cluster of basic residues (motif 2) in the stalk region. Scale bar represents 250 µm. (d) Schematic of receptor deletion constructs and their relative binding to E18 rat brain tissue compared with soluble NgR1 (NgR1(∆GPI)). Soluble NgR1 (red) and NgR3 (yellow), but not NgR2 (green), bound strongly to brain tissue sections. The LRRs of NgR1, which were previously shown to participate in myelin inhibitor binding, were dispensable for binding to neural tissue. Deletion of a cluster of basic amino acid residues in the C-terminal region of the NgR1 and NgR3 stalk (motif 2) or replacement of these residues with alanines (NgR1(7ala)) completely abolished binding. (e) Sequence alignment of binding motif 1 and motif 2 of NgR1 and NgR3. In the LRR C-terminal domain, residues F278 and R279 in NgR1 and residues F273 and R274 in NgR3 (motif 1) are important for GAG binding. Motif 2 is comprised of a cluster of basic amino acids, including residues 414-426 in NgR1 and residues 403-415 in NgR3. The basic residues of motif 1 and motif 2 are highlighted.
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CT GPI Percentage binding to brain tissue Stalk a b e d c npg a r t I C l e S To further characterize the relation of CSPG and MAI binding sites on NgR1, we generated a chimeric receptor construct in which the GAG-binding portion of NgR1 (amino acid residues 278-445) was replaced by the corresponding non-GAG-binding sequence of NgR2 (amino acid residues 281-420). Nogo66, MAG and OMgp bound strongly to this chimeric NgR1-NgR2 receptor, indicating that the GAG-binding sequences of NgR1 are not necessary for MAI binding ( Fig. 4a) . A soluble form of this same chimeric receptor failed to bind to rat brain tissue sections or to GAGs directly ( Supplementary  Fig. 5d-e ). This suggests that MAIs and CSPGs bind to distinct and dissociable sites on NgR1 (Fig. 4b) . Moreover, the presence of CS-B, CS-D or CS-E did not substantially influence binding of AP-Nogo66 to NgR1 (Fig. 4c) .
Neuronal NgRs participate in CSPG inhibition
To determine whether loss of NgRs leads to disinhibition of neurite growth on substrate-bound CSPGs, we analyzed CGNs from Ngr single and compound mutants ( Fig. 5 ). Loss of Ngr1 or Ngr3 alone, or the combined loss of Ngr1 and Ngr2 (Ngr1 −/− ; Ngr2 −/− ), was not sufficient to attenuate CSPG inhibition. Loss of all three Ngr genes (Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− ), however, resulted in significant (P < 0.001, one way ANOVA, Tukey's post hoc), yet incomplete, release of CSPG inhibition. Furthermore, release of inhibition for CGNs isolated from Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− and Rptpσ −/− pups was comparable ( Fig. 5) .
Dose-response experiments revealed that, when challenged with high concentrations of CSPGs, Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− and Rptpσ −/− neurons were strongly inhibited and lost their growth advantage over wild-type neurons (Supplementary Fig. 6a ). This suggests that these receptor systems share some degree of functional redundancy. At high doses of CSPGs, loss of NgRs may be compensated for by RPTPσ and vice versa. NgRs are not abundantly expressed in P7 DRGs 15 and Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− DRG neurons are not disinhibited on CSPG substrate. In a parallel experiment with DRG neurons from Rptpσ −/− mice, neurite length was increased on CSPGs (Supplementary Fig. 6b ). Collectively, these findings indicate that NgR1 and NgR3 bind CS-GAGs directly and participate in CSPG-mediated neurite outgrowth inhibition in a neuronal cell type-specific manner. a r t I C l e S NgR1 and NgR3 associate in a ligand-dependent manner NgRs are GPI-anchored proteins and therefore depend on interactions with transmembrane receptor components to signal growth inhibition across the neuronal plasma membrane. To assess whether NgR1 and NgR3 employ shared signaling mechanisms, we assayed binding of NgR3-Fc to the previously identified NgR1 receptor components p75, TROY and Lingo-1 in COS-7 cells. We observed no binding of soluble NgR3 to p75, TROY, Lingo-1 or NgR1 (Supplementary Fig. 4 ).
There have been conflicting results on whether NgR1 and NgR3 interact 32, 33 . We therefore revisited this issue and found that NgR1 and NgR3 were part of the same immune complex when coexpressed in HEK293T cells. The NgR1-NgR3 association was ligand dependent and was only observed in the presence of exogenously applied CSPGs (Supplementary Fig. 4 ), suggesting that the two receptors may be part of the same receptor complex. In this same assay, no association of NgR1 with NgR2 was observed, either in the presence or the absence of CSPGs. We next examined whether NgR1, NgR3 and p75 may be part of the same receptor complex. In HEK293T cells co-transfected with NgR1, NgR3 and p75, NgR1 pull-down revealed that the three receptors were present in the same immune complex if cells were treated with CSPGs ( Supplementary Fig. 4) .
To directly test whether p75 is important for CSPG-mediated neurite outgrowth inhibition, we plated P7 CGNs from p75 −/− mice on substrate-bound CSPGs. Loss of p75 did not result in a substantial release of CSPG inhibition (Supplementary Fig. 4 ). Together, these data indicate that p75, NgR1 and NgR3 interact in the presence of CSPGs, but p75 is not necessary for CSPG-mediated outgrowth inhibition. Our findings confirm and expand on previous work showing that the versican isoform V2 mediates neurite outgrowth inhibition in CGNs and DRG neurons in a p75-independent manner 17 .
CSPGs in the injured CNS support binding of NgR1 and NgR3
Similar to other CNS fiber tracts, severed retinal ganglion cell (RGC) axons in the rodent optic nerve fail to show spontaneous longdistance axonal regeneration. Retro-orbital crush injury to the optic nerve results in a global upregulation of CSPGs along the nerve 34 . Injured, but not control, optic nerve sections supported enhanced binding of soluble NgR1-Fc and NgR3-Fc, and the GAG-binding motif 2 of NgR1 and NgR3 was necessary for this binding (Fig. 6) . Moreover, binding of soluble receptors was largely abrogated by pretreatment of injured optic nerve sections with Ch'aseABC. Residual binding of NgR1-Fc was likely a result of association with endogenous MAIs (Fig. 6) . These findings suggest that CSPGs are endogenous ligands for neuronal NgR1 and NgR3.
Regeneration is enhanced in Ngr1 −/− ; Ngr3 −/− mice In the adult mouse retina, NgR1, NgR2 and NgR3 were all strongly expressed in RGCs (Fig. 7a) . Retinal stratification ( Fig. 7b) and optic nerve myelination (Fig. 7c) in Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice appeared to be normal. To assess RGC axon targeting to the superior colliculus, the suprachiasmatic nucleus and the lateral geniculate nucleus, we injected the right eye of adult wild-type and Ngr1 npg a r t I C l e S innervation were observed ( Fig. 7d-f) . Thus, germline ablation of all three NgRs does not appear to compromise retinal stratification, optic nerve myelination or RGC axonal pathfinding.
To assess whether NgRs contribute to the regenerative failure of injured CNS axons, we performed retro-orbital optic nerve crush injury in Ngr single and compound mutant mice. Compared with injured wild-type controls, Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice showed a modest, but significant (P < 0.001, one way ANOVA, Tukey's post hoc), increase in RGC axon regeneration ( Fig. 8) . At Loss of Ngr1, Ngr2 or Ngr3 alone, or the combined loss of Ngr1 and Ngr2, did not result in substantially enhanced RGC axon regeneration compared with wild-type mice ( Fig. 8, Supplementary Fig. 7 and Supplementary Table 1 ). However, Ngr1 −/− ; Ngr3 −/− mice showed a similar degree of axon regeneration as Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice. This suggests that NgR3 is involved in signaling neuronal growth inhibition. When coupled with our findings from neurite outgrowth studies in vitro, that NgR1 and NgR3 operate as functionally redundant CSPG receptors, this suggests that the optic nerve regeneration in Ngr1 −/− ; Ngr3 −/− and Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice is at least in part a reflection of decreased CSPG inhibition.
As Rptpσ is expressed in adult RGCs 27 , we examined whether the combined loss of Ngr1 and Ngr3 on an Rptpσ −/− background (Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− ) results in a further increase of regenerating axons. Few regenerating axons were observed in Rptpσ −/− single mutants, with no significant difference compared with wild-type controls (P > 0.05). Compared with Ngr1 −/− ; Ngr3 −/− mutants, Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− mutants showed a further increase in the number of regenerating axons (P < 0.001, one way ANOVA, Tukey's post hoc), suggesting a genetic interaction among these receptors ( Fig. 8, Supplementary Fig. 7 and Supplementary Table 1 ).
An advantage of optic nerve regeneration studies is that the growth potential of RGCs can be sensitized by intraocular injection of the yeast cell wall extract Zymosan, resulting in the release of RGC survival and growth-promoting factors, including oncomodulin 35 , ciliary neurotrophic factor and leukemia inhibitory factor 36 . Wild-type mice that received intraocular Zymosan showed greatly npg a r t I C l e S enhanced regeneration of RGC axons, exceeding the regeneration observed in Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− and Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− mice that were not treated with Zymosan (Fig. 8) . Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice that received intraocular Zymosan showed significantly more (P < 0.05, one way ANOVA, Tukey's post hoc) regenerating axons than wild-type, Ngr1 −/− , Ngr2 −/− , Ngr3 −/− or Rptpσ −/− mutants, as well as Ngr1 −/− ; Ngr2 −/− mutants, subjected to intraocular Zymosan. Ngr1 −/− ; Ngr3 −/− and Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice treated with intraocular Zymosan showed a similar regeneration phenotype. At several distances from the injury site, Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− mutants with intraocular Zymosan showed a further increase in the number of regenerating axons compared to Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice with intraocular Zymosan (P < 0.05, one way ANOVA, Tukey's post hoc; Fig. 8, Supplementary Fig. 7 and Supplementary Table 1 ).
In mice, optic nerve injury leads to the death of ~70% of RGCs by 2 weeks post-injury (Supplementary Fig. 8) . The enhanced regeneration observed in Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice was not a result of increased RGC survival, as similar numbers of injury-induced RGC death were observed in wild-type mice and Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mutants. Intraocular Zymosan administration partially protected RGCs from axotomy-induced cell death; however, the protective effect of Zymosan is similar in wild-type and Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice (Supplementary Fig. 8) . Consistent with the view that a decrease in RGC death was not sufficient to promote axonal regeneration, p53deficient RGCs was more resistant to injury-induced cell death, but fail to show enhanced regeneration 1 . To assess whether intraocular Zymosan influences expression of NgRs or RPTPσ in RGCs, we performed in situ hybridization at 3 and 7 d post-Zymosan injection, but did not observe any obvious changes (Supplementary Fig. 9 ).
DISCUSSION
Here we identified two previously unknown CSPG receptors. We found that NgR1 and NgR3 bound directly and with high affinity to select types of CS-GAGs and operated as functionally redundant CSPG receptors. Loss of Ngr family members individually was not sufficient to overcome CSPG inhibition; however, the combined loss of Ngr1 and Ngr3 led to a significant release of CSPG inhibition (P < 0.05). In Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mutants, severed RGC axons showed enhanced regenerative growth. Notably, Ngr1 −/− ; Ngr3 −/− , but not Ngr1 −/− ; Ngr2 −/− mutants, phenocopied the optic nerve regeneration phenotype of Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice. A further enhancement of axon regeneration was observed in Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− mutants, revealing a genetic interaction among NgR family members and the previously identified CSPG receptor RPTPσ. Collectively, our findings provide evidence for shared receptor mechanisms for prototypic myelin inhibitors and CSPGs, two major classes of growth inhibitory molecules that are abundant in the adult mammalian CNS.
NgR1 and NgR3 bind with high selectivity to CS-GAGs CSPG inhibition depends on the presence of CS-GAG chains; we therefore explored the molecular basis of NgR-GAG interactions. We identified two sequence motifs in each receptor, both of which are necessary for GAG binding. Motif 1 is located in the LRR-CT capping domain and is identical to the GT1b binding motif identified in NgR1 (ref. 31 ). Motif 2 is located in the distal stalk region juxtaposed to the GPI anchor.
NgR1 and NgR3 showed exquisite specificity toward select types of CS-GAGs. Binding to monosulfated CS-B, but not CS-A or CS-C, was very robust. In addition, the disulfated GAGs CS-D and CS-E bound strongly to NgR1 and NgR3. Identical binding preferences were observed for RPTPσ. Competition of soluble NgR1 and RPTPσ(1-3) ectodomain for CS-E binding suggests that two very different protein modules complex with at least partially overlapping CS-GAG structures. Dose-response experiments revealed that the loss of all of the Ngr genes or Rptpσ was sufficient to attenuate inhibition of neurite outgrowth at low and intermediate, but not at high, doses of CSPGs. A recent study identified the receptor tyrosine phosphatase LAR as a CSPG receptor 37 . Together, these findings reveal a substantial degree of functional redundancy among CSPG receptor mechanisms and suggest that antagonism of multiple NgR and LAR family members will be required to fully overcome CSPG inhibition.
Additive effects of extrinsic and intrinsic pathways
The relatively modest regeneration phenotype observed in Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− and Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− mice at 2 weeks post-injury is consistent with previous findings that expression of a dominant-negative form of NgR1 in RGCs 38 or blocking of RhoA with C3 transferase 39 is not sufficient to promote substantial regeneration of severed optic nerve axons. In a similar vein, removal of one or several MAIs results in inconsistent and often poor regeneration in spinal cord-injured mice 28, 29 . Collectively, mouse genetic studies suggest that germline ablation of multiple growth inhibitory ligands or receptors is not sufficient to promote robust and long-distance regeneration in different fiber tracts of the injured adult CNS.
A substantial effect of environmental inhibitory signals on limiting axon regeneration was revealed, however, when genetic manipulations were combined with activation of RGC intrinsic growth programs. On an Ngr1 −/− ; Ngr3 −/− , Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− or Ngr1 −/− ; Ngr3 −/− ; Rptpσ −/− background, intraocular Zymosan injection resulted in significantly enhanced axonal growth distal to the injury site compared with wild-type, Ngr1 −/− ; Ngr2 −/− or Rptpσ −/− mutant mice with intraocular Zymosan. Although the additive effects of simultaneous release of growth inhibitory mechanisms and activation of intrinsic growth programs have been reported 38, 40, 41 , our data indicate that, in growth-enabled RGCs, members of the NgR family and LAR family collaborate to negatively affect the number and length of regenerating axons following CNS injury.
NgR3 participates in neuronal growth inhibition
Enhanced axon regeneration observed in the optic nerve of Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− mice was mimicked by Ngr1 −/− ; Ngr3 −/− , but not by Ngr1 −/− ; Ngr2 −/− , mutants. This suggests that, on an Ngr1 −/− background, NgR3, but not NgR2, contributes to the regenerative failure of severed RGC axons. As NgR3 does not directly associate with Nogo, MAG or OMgp, but supports CSPG binding and participates in CSPG inhibition in vitro, our findings suggest that NgR3-CSPG-mediated growth inhibition contributes to the regenerative failure of CNS axons in vivo.
Although CSPGs are the first ligands identified for NgR3, they also bind to NgR1, further underscoring the high promiscuity of NgR1. CSPGs are found in crude CNS myelin preparations 17, 42 and were present in the CNS myelin that we used (data now shown). Similar to the enhanced neurite outgrowth of Ngr1 −/− ; Ngr2 −/− ; Ngr3 −/− neurons on CNS myelin (Fig. 1) , the enhanced growth of neurons functionally depleted of Ngr1 and PirB 10 may be, at least in part, a reflection of decreased MAI and CSPG inhibition.
Implications for experience-dependent neural plasticity
Although it has been known for some time that MAIs and CSPGs share similar downstream signaling pathways 16, 17 , the level at which MAI and CSPG signaling cascades converge to regulate neuronal npg a r t I C l e S cytoskeletal dynamics has not yet been determined. We identified NgR1 and NgR3 as functionally redundant CSPG receptors. We provide evidence that Nogo, MAG, OMgp and CSPGs share receptor components and perhaps signal through related receptor complexes to block neuronal plasticity, sprouting and axonal regeneration. In support of this idea, the myelin inhibitor Nogo-A shares structural and sequential similarities with neurocan, an inhibitory CSPG that has been implicated in blocking neuronal regeneration 43 , suggesting a common origin for two seemingly unrelated inhibitors of growth. The newly discovered connection between CSPGs and NgRs is not only relevant for neuronal repair, but may also provide a mechanistic explanation for why two seemingly unrelated manipulations, such as Ch'aseABC infusion into the mature visual cortex and germline ablation of Ngr1 or Nogo result in enhanced ocular dominance plasticity following monocular deprivation 21, 44 . Mounting evidence suggests that mechanisms that limit neuronal growth and plasticity following CNS injury and disease resemble those that negatively regulate neuronal growth and synaptic structure under physiological conditions 45, 46 .
The identification of NgRs as shared receptors for MAIs and CSPGs provides new insights into how a diverse group of inhibitory cues regulates neuronal structure and function under physiological conditions and following injury. We propose that NgRs are part of a multicomponent receptor system that serves as a signaling platform to initiate pathways that limit neuronal growth and increase structural stability of synapses. When combined with recent findings that NgR1and its ligands Nogo and OMgp influence synaptic transmission 47 , experience-dependent network refinement 44 and spatial memory 48 , our results expand the function of these molecules beyond neural repair and shed light on a vital part of the neuronal machinery that limits growth and plasticity in CNS health and disease.
METhODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/natureneuroscience/.
Note: Supplementary information is available on the Nature Neuroscience website.
To assess axon density and myelination, optic nerves were embedded in epon and stained with Toluidine blue. To assess retinal ganglion cell death at various time points following optic nerve injury, retinal sections were stained with antibody to class III β-tubulin (TuJ1) and, in some instances, with antibody to active caspase-3 (Promega).
For intraocular injections of anterograde tracer, 6-week-old mice received bilateral injections (2 µl) of 1 µg µl −1 Alexa 488-and Alexa 594-conjugated cholera toxin β (Invitrogen) in the left and right eye, respectively. Mice were perfused transcardially 5 d post-injection and their brains were dissected, post-fixed in 4% paraformaldehyde overnight and cryoprotected in 30% sucrose overnight. Brain tissue was embedded in OCT Tissue-Tek Medium (Sakura Finetek) and coronal sections (50 µm thick) were imaged.
To visualize regenerating axons in the injured optic nerve, eyes with optic nerves attached were dissected, post-fixed and cryoprotected. Optic nerves were embedded and longitudinal sections (14 µm thick) were stained with antibody to GAP-43. The appropriate Alexa Fluor-conjugated secondary antibody (Invitrogen) was then used for fluorescent labeling.
Statistical analysis. For quantification of neurite outgrowth, UTHSCSA ImageTool for Windows was used, and processes equal or longer to approximately one cell body diameter were measured. For each condition, at least 150 neurites were quantified, and the mean ± s.e.m. of neurite length for each genotype was determined from multiple independent experiments. For quantification of retinal ganglion cell death, the density of TuJ1-positive cells in the ganglion cell layer per field of view (at least ten sections, three independent experiments per condition) was counted. For quantification of activated caspase-3-positive retinal ganglion cells, the number of cells labeled for activated caspase-3 was calculated as a percentage of the total number of cells (TuJ1 positive) per field of view (at least ten sections, three independent experiments per condition). Quantification of optic nerve binding assays and in situ hybridization (at least 20 sections, four independent experiments per condition) was performed as previously described 50 , using Microsuite Five (Olympus) quantification software. All data were analyzed using ANOVA followed by Tukey's post hoc comparisons. All statistics were performed using SigmaStat 3.0 for Windows (Systat Software).
To assess regenerative axonal growth, the number of GAP-43-positive axons at prespecified distances from the injury site was counted in at least three sections per nerve. These numbers were converted into the number of regenerating axons per nerve at various distances as described previously 38 . All data were analyzed using ANOVA followed by Tukey's post hoc comparisons. All statistics were performed using GraphPad Prism 5.00 (GraphPad Software). Our finding that loss of all three Ngr genes elicited significant retinal ganglion cell regeneration was based on two independently generated datasets produced by two independent surgeons (K.T.B. and Y. Koriyama). Both datasets were analyzed separately and led to the same conclusions ( Supplementary Table 1 ). In addition, no significant differences in axon regeneration following injury (with or without intraocular Zymosan injection) were observed between mice on three different genetic backgrounds (129, C57BL/6 and BALB/c) (P > 0.05, data not shown). 
